FI109131B - Förfarande för separering av rekombinerade mikro-organismer, på vilkas yta åtminstone en molekyl har enzymatisk aktivitet - Google Patents
Förfarande för separering av rekombinerade mikro-organismer, på vilkas yta åtminstone en molekyl har enzymatisk aktivitet Download PDFInfo
- Publication number
- FI109131B FI109131B FI942469A FI942469A FI109131B FI 109131 B FI109131 B FI 109131B FI 942469 A FI942469 A FI 942469A FI 942469 A FI942469 A FI 942469A FI 109131 B FI109131 B FI 109131B
- Authority
- FI
- Finland
- Prior art keywords
- solid support
- molecule
- enzymatic activity
- phages
- microorganisms
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000002255 enzymatic effect Effects 0.000 title claims abstract description 39
- 239000007787 solid Substances 0.000 claims abstract description 44
- 229940125808 covalent inhibitor Drugs 0.000 claims abstract description 24
- 102000004190 Enzymes Human genes 0.000 claims description 36
- 108090000790 Enzymes Proteins 0.000 claims description 35
- 238000000926 separation method Methods 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003446 ligand Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 108010090804 Streptavidin Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 230000003197 catalytic effect Effects 0.000 claims description 7
- 108090001008 Avidin Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 125000000524 functional group Chemical group 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 claims description 3
- 125000002228 disulfide group Chemical group 0.000 claims description 3
- 238000006911 enzymatic reaction Methods 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 2
- 150000002009 diols Chemical group 0.000 claims description 2
- 239000002981 blocking agent Substances 0.000 claims 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000013038 irreversible inhibitor Substances 0.000 claims 1
- 239000012466 permeate Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 49
- 108090000204 Dipeptidase 1 Proteins 0.000 description 45
- 102000006635 beta-lactamase Human genes 0.000 description 40
- 229940088598 enzyme Drugs 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 28
- 239000000047 product Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000000700 radioactive tracer Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 239000003550 marker Substances 0.000 description 14
- 108090000656 Annexin A6 Proteins 0.000 description 13
- 102100034278 Annexin A6 Human genes 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 206010010144 Completed suicide Diseases 0.000 description 9
- 108010074860 Factor Xa Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- -1 methoxymethyl ester Chemical class 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108010051423 streptavidin-agarose Proteins 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000724791 Filamentous phage Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- NGHVIOIJCVXTGV-UHFFFAOYSA-N 6beta-amino-penicillanic acid Natural products OC(=O)C1C(C)(C)SC2C(N)C(=O)N21 NGHVIOIJCVXTGV-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000536 complexating effect Effects 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical compound [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000702374 Enterobacteria phage fd Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000012072 active phase Substances 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- VHCSBTPOPKFYIU-UHFFFAOYSA-N 2-chloroethanesulfonyl chloride Chemical compound ClCCS(Cl)(=O)=O VHCSBTPOPKFYIU-UHFFFAOYSA-N 0.000 description 2
- BWRRWBIBNBVHQF-UHFFFAOYSA-N 4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)butanoic acid Chemical compound O1C(CCCC(=O)O)=NC(C=2N=CC=CC=2)=N1 BWRRWBIBNBVHQF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001484259 Lacuna Species 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 125000003460 beta-lactamyl group Chemical group 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- MWFJXRUUPWIALU-UHFFFAOYSA-N ethyl ethenesulfonate Chemical compound CCOS(=O)(=O)C=C MWFJXRUUPWIALU-UHFFFAOYSA-N 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012073 inactive phase Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 2
- 229910001623 magnesium bromide Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- NZVYQOWVZYRUON-UHFFFAOYSA-M sodium 3-amino-1-[(4-nitrophenyl)methoxy]-1-oxopropane-2-sulfonate Chemical compound [N+](=O)([O-])C1=CC=C(COC(=O)C(CN)S(=O)(=O)[O-])C=C1.[Na+] NZVYQOWVZYRUON-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- LWPHUVGDBNUVHA-GXZWQRSESA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-[2-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethylamino]-3-oxopropyl]disulfanyl]propanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCNC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O LWPHUVGDBNUVHA-GXZWQRSESA-N 0.000 description 1
- KWFXTKHPKNQZRT-UHFFFAOYSA-N 1,1-dichloroethane;ethyl acetate Chemical compound CC(Cl)Cl.CCOC(C)=O KWFXTKHPKNQZRT-UHFFFAOYSA-N 0.000 description 1
- GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 1
- JKTYGPATCNUWKN-UHFFFAOYSA-N 4-nitrobenzyl alcohol Chemical compound OCC1=CC=C([N+]([O-])=O)C=C1 JKTYGPATCNUWKN-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241001429175 Colitis phage Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 description 1
- 101100338242 Drosophila virilis His1.1 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710136739 Teichoic acid poly(glycerol phosphate) polymerase Proteins 0.000 description 1
- 102220472589 Vitamin K epoxide reductase complex subunit 1_S68A_mutation Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 101150049515 bla gene Proteins 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10051—Methods of production or purification of viral material
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
Claims (25)
1. Förfarande för väljande av rekombinerade mikroorganismer, vilka pä sin yta uppvisar ätminstone en molekyl med enzymatisk aktivitet, kannetecknat av att de rekombinerade mikroorganis-merna immobiliseras pä en fast bärare med hjälp av en kovalent inhibitor för det aktiva läget av molekylen med enzymatisk ak- *:*. tivitet, vilken inhibitor är bunden tili den fasta bäraren med . .·. en arm, varvid armen innefattar en utbrytbar kemisk funktionell grupp och att de rekombinerade mikroorganismerna eller deras hela genom eller en del av det tillvaratas och att deras hela * · · / genom eller en del av det isoleras. * · · »
2. Avskiljningsförfarande i enlighet med patentkrav 1, känne-tecknat av att innan de rekombinerade mikroorganismerna immobi-liseras pä den fasta bäraren märks de med den kovalenta inhibi- , ···, torn för den nämnda molekylens aktiva läge, vilken inhibitor är bunden via nämnda arm till en ligand som kan immobiliseras pä den fasta bäraren. * »
3. Avskiljningsförfarande i enlighet med vilket som heist av patentkraven 1 eller 2, kannetecknat av att mikroorganismerna : utgör virus, fördelaktigt fager, exempelvis trädlika fager. 109131
4. Avskiljningsförfarande i enlighet med vilket som heist av patentkraven l eller 2, kännetecknat av att mikroorganismerna är fagemider.
5. Avskiljningsförfarande i enlighet med vilket som heist av de föregäende patentkraven, kännetecknat av att den fasta bära-ren bestär av en kromatografisk kolonn pä vilken avidin, streptavidin och/eller en antikropp har immobiliserats.
6. Avskiljningsförfarande i enlighet med vilket som heist av de föregäende patentkraven, kännetecknat av att molekylerna med enzymatisk aktivitet har utvalts frän gruppen bestäende av en-zymer, abzymer, katalytiska peptider eller en blandning av des-sa.
7. Förfarande i enlighet med vilket som heist av de föregäende patentkraven, kännetecknat av att mikroorganismerna tillva-ratas genom att avskilja dem frän den fasta bäraren.
8. Avskiljningsförfarande i enlighet med vilket som heist av de föregäende patentkraven, kännetecknat av att de rekombinera-de mikroorganismerna tillvaratas genom att avskilja nämnda anne som förenar den kovalenta inhibitorn med den fasta bäraren. t ·
9. Avskiljningsförfarande i enlighet med vilket som heist av patentkraven 1-7, kännetecknat av att de rekombinerade mikroor-ganismerna tillvaratas genom att avskilja liganden frän den fasta bäraren med en eluerande lösning, fördelaktigt en lösning . med surt pH.
10. Avskiljningsförfarande i enlighet med vilket som heist av patentkraven 1-7, kännetecknat av att de rekombinerade mikroor-ganismerna tillvaratas genom att avskilja bindningen mellan den ; kovalenta inhibitorn och molekylen med enzymatisk aktivitet.
’ * 11. Avskiljningsförfarande i enlighet med vilket som heist av patentkraven 1-7, kännetecknat av att de rekombinerade mikroor-ganismerna tillvaratas genom att avskilja peptidbindningen mellan molekylen med enzymatisk aktivitet och mikroorganismen. 33 1 09 1 31
12. Avskiljningsförfarande i enlighet med patentkrav 11, kän-netecknat av att avskiljningen utförs med hjälp av en proteas.
13. Avskiljningsförfarande i enlighet med patentkrav 11, kän-netecknat av att avskiljningen utförs med cyanogenbromid.
14. Avskiljningsförfarande i enlighet med patentkrav 11, kän-netecknat av att avskiljningen utförs med hydroxylamin.
15. Avskiljningsförfarande i enlighet med vilket som heist av patentkraven 1-7, kännetecknat av att de rekombinerade mikroor-ganismerna förstörs och att deras hela genom eller en del av det tillvaratas, isoleras och klonas.
16. Spärämne som kan användas i förfarandet enligt vilket som heist av de föregäende patentkraven, kännetecknat av att det bestär av en kovalent inhibitor för det aktiva läget av en mo-lekyl med enzymatisk aktivitet som är bunden, via en arm inne-hallande en avskiljbar kemisk funktionell grupp, med en ligand som kan immobiliseras pa en fast bärare.
17. Spärämne i enlighet med patentkrav 16, kännetecknat av att den kovalenta inhibitorn är en irreversibel inhibitor.
* · ; .·. 18. Spärämne i enlighet med patentkrav 16 eller 17, känneteck- ! nat av att liganden är ett biotin eller ett iminobiotin. ! i »
19. Spärämne i enlighet med vilket som heist av patentkraven ...*** 16-18, kännetecknat av att nämnda arm innehäller en disulfid- : funktionell grupp.
, 20. Spärämne i enlighet med vilket som heist av patentkraven • · 16-19, kännetecknat av att den kovalenta inhibitorn är en ana- • · ·;*’ log av den specif ikä övergängsfas av den enzymatiska reaktionen :\j som molekylen med enzymatisk aktivitet genomgär. « » ' « I
, 21. Förfarande för framställning av spärämnet enligt vilket som heist av patentkraven 16-20, kännetecknat av att en kova-> ' lent inhibitor för det aktiva läget av molekylen med enzymatisk aktivitet ansluts via nämnda arm till en ligand som kan immobiliseras pä en fast bärare. 34 109131
22. Fast bärare som kan användas i förfarandet enligt vilket som heist av patentkraven 1-15, kännetecknad av att den inne-fattar en kovalent inhibitor för det aktiva läget av molekylen med enzymatisk aktivitet som är förbunden vid en fast bärare via en arm, vilken arm innehäller en avskiljbar kemisk funktio-nell grupp.
23. Fast bärare i enlighet med patentkrav 22, kännetecknad av att den kovalenta inhibitorn som är bunden vid den fasta bära-ren bestär av spärämnet i enlighet med patentkraven 17-20.
24. Fast bärare i enlighet med patentkrav 22, kännetecknad av att armen är bunden vid den fasta bäraren med en esterbindning eller den innehäller en bredvidliggande diol.
25. Förfarande för framställning av en fast bärare i enlighet med vilket som heist av patentkraven 22-24, kännetecknat av att en kovalent inhibitor för det aktiva läget av molekylen med enzymatisk aktivitet binds via nämnda arm till en fast bärare. • · · • · • · * # · * > · • ·« · * · * · · • t < · f I ’ t · • » · f * * » 3 t < » t ' # ’ > »
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE9101106 | 1991-11-29 | ||
| BE9101106A BE1006312A3 (fr) | 1991-11-29 | 1991-11-29 | Procede de selection de microorganismes recombinants comportant a leur surface au moins une molecule a activite enzymatique. |
| PCT/BE1992/000052 WO1993011242A1 (fr) | 1991-11-29 | 1992-11-30 | Procede de selection de microorganismes recombinants comportant a leur surface au moins une molecule a activite enzymatique |
| BE9200052 | 1992-11-30 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI942469A0 FI942469A0 (sv) | 1994-05-26 |
| FI942469A FI942469A (sv) | 1994-05-26 |
| FI109131B true FI109131B (sv) | 2002-05-31 |
Family
ID=3885823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI942469A FI109131B (sv) | 1991-11-29 | 1994-05-26 | Förfarande för separering av rekombinerade mikro-organismer, på vilkas yta åtminstone en molekyl har enzymatisk aktivitet |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0617737B1 (sv) |
| JP (1) | JP4125364B2 (sv) |
| KR (1) | KR100243997B1 (sv) |
| AT (1) | ATE147783T1 (sv) |
| AU (1) | AU671089B2 (sv) |
| BE (1) | BE1006312A3 (sv) |
| BR (1) | BR9206970A (sv) |
| CA (1) | CA2124580C (sv) |
| DE (1) | DE69216853T2 (sv) |
| DK (1) | DK0617737T3 (sv) |
| ES (1) | ES2098555T3 (sv) |
| FI (1) | FI109131B (sv) |
| HU (1) | HU220876B1 (sv) |
| NO (1) | NO313593B1 (sv) |
| SG (1) | SG48094A1 (sv) |
| WO (1) | WO1993011242A1 (sv) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA931263B (en) * | 1992-02-24 | 1993-11-02 | Igen Inc | Reaction-based selection for expression of and concentration of catalytic moieties |
| CA2368875A1 (en) | 1999-04-14 | 2000-10-19 | The Government Of The United States Of America | High sensitivity phage display biomolecule detection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5325030B2 (sv) * | 1972-12-19 | 1978-07-24 | ||
| US4165258A (en) * | 1975-10-08 | 1979-08-21 | University Of Pennsylvania | Plasminogen activating enzyme-specific competitive inhibitor |
| CA1313111C (en) * | 1986-12-01 | 1993-01-26 | William J. Hubbard | Method of identifying unknown organisms |
| DE3833628A1 (de) * | 1988-10-03 | 1990-04-12 | Genlux Forschungsgesellschaft | Verfahren zum nachweis und zur identifikation toxischer substanzen mit hilfe klonierter mikroorganismen |
| EP0437537B1 (en) * | 1988-10-04 | 1997-02-26 | DNA Plant Technology Corporation | Bacterial detection by phage transduction of detectable phenotype |
| JP2810138B2 (ja) * | 1989-08-23 | 1998-10-15 | 昭和電工株式会社 | 酵素活性測定用充填剤、その使用方法および装置 |
| ES2062394T3 (es) * | 1989-09-29 | 1994-12-16 | Rohm & Haas | Medio que contiene un ligando para la separacion cromatografica, procedimiento para la preparacion del medio y uso del medio para aislar moleculas naturales o sinteticas de una mezcla liquida. |
-
1991
- 1991-11-29 BE BE9101106A patent/BE1006312A3/fr not_active IP Right Cessation
-
1992
- 1992-11-30 WO PCT/BE1992/000052 patent/WO1993011242A1/fr active IP Right Grant
- 1992-11-30 DK DK92923617.2T patent/DK0617737T3/da active
- 1992-11-30 KR KR1019940701814A patent/KR100243997B1/ko not_active IP Right Cessation
- 1992-11-30 SG SG1996007002A patent/SG48094A1/en unknown
- 1992-11-30 HU HU9401593A patent/HU220876B1/hu unknown
- 1992-11-30 ES ES92923617T patent/ES2098555T3/es not_active Expired - Lifetime
- 1992-11-30 CA CA002124580A patent/CA2124580C/en not_active Expired - Lifetime
- 1992-11-30 JP JP50965793A patent/JP4125364B2/ja not_active Expired - Lifetime
- 1992-11-30 EP EP92923617A patent/EP0617737B1/fr not_active Expired - Lifetime
- 1992-11-30 AT AT92923617T patent/ATE147783T1/de active
- 1992-11-30 BR BR9206970A patent/BR9206970A/pt not_active IP Right Cessation
- 1992-11-30 AU AU29373/92A patent/AU671089B2/en not_active Expired
- 1992-11-30 DE DE69216853T patent/DE69216853T2/de not_active Expired - Lifetime
-
1994
- 1994-05-10 NO NO19941731A patent/NO313593B1/no not_active IP Right Cessation
- 1994-05-26 FI FI942469A patent/FI109131B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HU9401593D0 (en) | 1994-08-29 |
| SG48094A1 (en) | 1998-04-17 |
| WO1993011242A1 (fr) | 1993-06-10 |
| JP4125364B2 (ja) | 2008-07-30 |
| HU220876B1 (en) | 2002-06-29 |
| JPH07505999A (ja) | 1995-07-06 |
| EP0617737A1 (fr) | 1994-10-05 |
| BR9206970A (pt) | 1995-12-19 |
| HUT70310A (en) | 1995-09-28 |
| BE1006312A3 (fr) | 1994-07-19 |
| ATE147783T1 (de) | 1997-02-15 |
| AU671089B2 (en) | 1996-08-15 |
| DK0617737T3 (da) | 1997-07-07 |
| AU2937392A (en) | 1993-06-28 |
| NO941731L (no) | 1994-06-21 |
| KR100243997B1 (ko) | 2000-02-01 |
| NO941731D0 (no) | 1994-05-10 |
| DE69216853D1 (de) | 1997-02-27 |
| DE69216853T2 (de) | 1997-06-26 |
| FI942469A0 (sv) | 1994-05-26 |
| EP0617737B1 (fr) | 1997-01-15 |
| NO313593B1 (no) | 2002-10-28 |
| FI942469A (sv) | 1994-05-26 |
| ES2098555T3 (es) | 1997-05-01 |
| CA2124580C (en) | 2002-07-16 |
| CA2124580A1 (en) | 1993-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | [15] Libraries of peptides and proteins displayed on filamentous phage | |
| US5338665A (en) | Peptide library and screening method | |
| JP6075658B2 (ja) | 方法及び組成物 | |
| US6194183B1 (en) | Phage display for detergent enzyme activity | |
| Soumillion et al. | Phage display of enzymes and in vitro selection for catalytic activity | |
| ES2491166T3 (es) | Miméticos de lazo de horquilla beta fijados a patrón y su utilización en exposición en fagos | |
| FI109131B (sv) | Förfarande för separering av rekombinerade mikro-organismer, på vilkas yta åtminstone en molekyl har enzymatisk aktivitet | |
| Geiger et al. | Convenient site-selective protein coupling from bacterial raw lysates to coenzyme A-modified tobacco mosaic virus (TMV) by Bacillus subtilis Sfp phosphopantetheinyl transferase | |
| US6642014B1 (en) | Enzyme activity screen with direct substrate replacement | |
| CN114213532B (zh) | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 | |
| WO1995020601A1 (en) | Reagents binding vinculin, dynein, and glutathione s-transferase from peptide libraries | |
| Bonnycastle et al. | Assaying phage-borne peptides by phage capture on fibrinogen or streptavidin | |
| ES2310969B1 (es) | Biotina-soporte poroso, metodos de obtencion y usos. | |
| Ku | A combinatorial approach towards molecular recognition | |
| Huang | A combinatorial approach towards DNA recognition | |
| Zhang | Protein engineering and gene profiling by phage display and yeast surface display | |
| Shroyer | Bacterial detection using phage display for the differentiation of pre-and post-infection bacteriophages: A model M13 system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |